Brian Linder, MD
Urology · Rochester, MNNPI 1659692630
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.7%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 62.5% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $2,441, more than ten times the $106 reported in 2020.
Across 31 payments — averaging $179.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Axonics, Inc.$1K
- AbbVie$857
- Boston Scientific$159
Across 45 payments — averaging $3371.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$152K
What the payments were for
- Consulting fees$77514%
- Speaking & faculty fees$2,00036%
- Travel & lodging$3116%
- Food & beverage$2,49145%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 18 | $3,485 |
| Axonics, Inc. | 8 | $1,076 |
| AbbVie | 2 | $857 |
| Boston Scientific | 3 | $159 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$2,512
- BOTOX$775
- Axonics$722
- Axonics r-SNM System$153
- ALTAVIVA$135
How this compares
$5,578 in reported general payments places this provider in the 80th percentile of 247 urology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 116 | $71,286 |
| MyrbetriqMirabegron | 58 | $42,026 |
| PremarinEstrogens, Conjugated | 11 | $4,771 |
| Methenamine Hippurate | 63 | $4,597 |
| Estradiol | 59 | $3,234 |
| Trospium Chloride | 21 | $1,124 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 55 | $536 |
| Gentamicin Sulfate | 16 | $270 |
| Cefdinir | 11 | $90 |
Paid to pharmacies, not to this prescriber.
Other urology in Rochester
- Jonathan WarnerRochester$144K
- Tobias KohlerRochester$89K
- Stephen BoorjianRochester$61K
- Robert KarnesRochester$29K
- Kevin WymerRochester$16K
- Paras ShahRochester$14K
- Matthew ZiegelmannRochester$9K
- Meghan CooperRochester$8K
- Sevann HeloRochester$6K
- Aaron PotretzkeRochester$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.